clinical trial · NCT05752461
SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
Beijing Suncadia Pharmaceuticals Co., Ltd·phase2·completed·n = 353
Prevention of Venous Thromboembolism After Knee ArthroplastySHR-2004 injectionSHR-2004 injectionSHR-2004 injectionEnoxaparin sodium injection
brief summary
The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty
started
Apr 12, 2023
primary completion
Apr 12, 2024
completion
Jun 25, 2024
last updated
Jan 20, 2025
official title
A Multicenter, Randomized, Active-comparator-controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of a Single Subcutaneous Injection of SHR-2004 in Patients Undergoing Elective Unilateral Total Knee Arthroplasty
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol